BerGenBio ASA

BerGenBio ASA
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

Links

Bergenbio.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BerGenBio ASA: Invitation to ASCO Update Call

Fri, May 31, 2019 14:07 CET

Bergen, Norway, 31 May 2019 – BerGenBio ASA (OSE:BGBIO), will share its latest updates and data on an investor call on 4 June 2019, during the annual American Society of Clinical Oncology (ASCO) meeting. BerGenBio’s senior management team will be hosting the call at 15:30 CET.Dial-in details are: · Standard International Dial-In: +44 (0) 2071 928000 · United States Dial-In: 16315107495 · Participant Code: 4352428 The call will focus on two peer reviewed abstracts on Phase II clinical data with bemcentinib in the treatment of Non-Small Cell Lung Cancer and Acute Myeloid

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

BerGenBio ASA: Invitation to ASCO Update Call

Subscribe

Media